Diversified Healthcare Trust

NasdaqGS:DHC Stock Report

Mkt Cap: US$177.6m

We’ve recently updated our valuation analysis.

Diversified Healthcare Trust Valuation

Is DHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DHC?

Other financial metrics that can be useful for relative valuation.

DHC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA17x
PEG Ratio-0.006x

Price to Earnings Ratio vs Peers

How does DHC's PE Ratio compare to its peers?

The above table shows the PE ratio for DHC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27x
NHHS NorthStar Healthcare Income
9.3xn/aUS$171.9m
UHT Universal Health Realty Income Trust
6.9xn/aUS$743.2m
GMRE Global Medical REIT
42.3x-11.1%US$726.1m
CHCT Community Healthcare Trust
49.5x18.1%US$999.3m
DHC Diversified Healthcare Trust
0.4x-76.9%US$177.6m

Price-To-Earnings vs Peers: DHC is good value based on its Price-To-Earnings Ratio (0.4x) compared to the peer average (27x).


Price to Earnings Ratio vs Industry

How does DHC's PE Ratio compare vs other companies in the US REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a4.8%
n/an/an/a

Price-To-Earnings vs Industry: DHC is good value based on its Price-To-Earnings Ratio (0.4x) compared to the US REITs industry average (27x)


Price to Earnings Ratio vs Fair Ratio

What is DHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DHC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.4x
Fair PE Ratio4.9x

Price-To-Earnings vs Fair Ratio: DHC is good value based on its Price-To-Earnings Ratio (0.4x) compared to the estimated Fair Price-To-Earnings Ratio (4.9x).


Share Price vs Fair Value

What is the Fair Price of DHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DHC ($0.74) is trading below our estimate of fair value ($0.79)

Significantly Below Fair Value: DHC is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DHC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.74
US$1.90
+156.4%
81.6%US$4.50US$0.50n/a4
Jan ’24US$0.65
US$1.90
+193.8%
81.6%US$4.50US$0.50n/a4
Dec ’23US$1.01
US$2.15
+112.9%
68.1%US$4.50US$0.50n/a4
Nov ’23US$1.36
US$2.90
+113.2%
45.4%US$5.00US$1.60n/a4
Oct ’23US$0.99
US$2.90
+192.9%
45.4%US$5.00US$1.60n/a4
Sep ’23US$1.43
US$2.90
+102.8%
45.4%US$5.00US$1.60n/a4
Aug ’23US$1.78
US$4.10
+130.3%
19.5%US$5.00US$3.00n/a5
Jul ’23US$1.89
US$4.10
+116.9%
19.5%US$5.00US$3.00n/a5
Jun ’23US$2.24
US$4.10
+83.0%
19.5%US$5.00US$3.00n/a5
May ’23US$2.25
US$4.30
+91.1%
25.0%US$6.00US$3.00n/a5
Apr ’23US$3.22
US$4.30
+33.5%
25.0%US$6.00US$3.00n/a5
Mar ’23US$2.73
US$4.51
+65.2%
32.7%US$6.50US$3.00n/a5
Feb ’23US$3.21
US$4.91
+53.0%
34.1%US$7.00US$3.00n/a5
Jan ’23US$3.09
US$4.71
+52.4%
31.0%US$6.50US$3.00US$0.655
Dec ’22US$2.61
US$4.65
+78.2%
25.8%US$6.50US$3.00US$1.015
Nov ’22US$3.83
US$5.15
+34.5%
27.4%US$7.50US$3.75US$1.365
Oct ’22US$3.53
US$4.96
+40.5%
27.4%US$7.50US$3.75US$0.996
Sep ’22US$3.81
US$4.93
+29.4%
25.5%US$7.50US$3.75US$1.437
Aug ’22US$3.90
US$4.58
+17.5%
16.9%US$6.00US$3.75US$1.786
Jul ’22US$4.25
US$4.63
+8.8%
17.0%US$6.00US$3.75US$1.896
Jun ’22US$3.74
US$4.63
+23.7%
17.0%US$6.00US$3.75US$2.246
May ’22US$4.42
US$4.63
+4.8%
17.0%US$6.00US$3.75US$2.256
Apr ’22US$4.75
US$4.55
-4.2%
18.5%US$6.00US$3.75US$3.225
Mar ’22US$4.67
US$4.20
-10.1%
25.9%US$6.00US$3.00US$2.735
Feb ’22US$4.31
US$4.05
-6.0%
20.8%US$5.00US$3.00US$3.215
Jan ’22US$4.12
US$4.05
-1.7%
20.8%US$5.00US$3.00US$3.095

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies